<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618758</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH_GS_IPEC</org_study_id>
    <nct_id>NCT03618758</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6</brief_title>
  <acronym>IPLUS</acronym>
  <official_title>Safety and Efficacy of Intraperitoneal Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis Receiving Systemic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for
      decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic
      chemotherapy. Intraperitoneal chemotherapy in combination with systemic chemotherapy is under
      many clinical trials mainly in Japan, and are showing promising results.

      This is Korea's first clinical trial on Intraperitoneal Paclitaxel with Systemic mFOLFOX6
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose determination (Phase 1)</measure>
    <time_frame>1 Year</time_frame>
    <description>Dosage determination of Intraperitoneal Paclitaxel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase 2)</measure>
    <time_frame>1 Year</time_frame>
    <description>1 year Overall survival with determined dose from Phase 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 Year</time_frame>
    <description>1 year Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity ratio</measure>
    <time_frame>3 Years</time_frame>
    <description>Toxicity occurrence ratio by CTCAE V.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 Years</time_frame>
    <description>Tumor response with RECIST criteria V.1.1 and Peritoneal Regression Grading Score(PRGS) system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion surgery ratio</measure>
    <time_frame>3 Years</time_frame>
    <description>Conversion surgery after stable disease or regression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Gastric Cancer Stage IV</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Intraperitoneal Paclitaxel</condition>
  <condition>mFOLFOX6</condition>
  <arm_group>
    <arm_group_label>Gastric Cancer with Peritoneal Carcinomatosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum
Phase 2: Intraperitoneal Paclitaxel with recommended dose</description>
    <arm_group_label>Gastric Cancer with Peritoneal Carcinomatosis</arm_group_label>
    <other_name>(Genexol®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6 regimen</intervention_name>
    <description>Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)</description>
    <arm_group_label>Gastric Cancer with Peritoneal Carcinomatosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven adenocarcinoma of gastric origin, primary or recurrent

          -  Identification of Peritoneal seeding by CT or diagnostic laparoscopy

          -  Patients confirmed to receive mFOLFOX6 on multidisciplinary outpatient clinic

          -  No previous history of chemotherapy or 4week after the last chemotherapy for gastric
             cancer

          -  Labs adequate for chemotherapy (within 2 weeks of enrollment)

          -  Absolute Neutrophil Count: ≧ 1,500/mm³

          -  Hemoglobin level: ≧ 8.0g/dL

          -  Platelet Count: ≧ 10×104/mm³

          -  AST (GOT), ALT (GPT): ≦ 100U/L

          -  Total Bilirubin: ≦ 2.0mg/dL

          -  Creatinine Clearance (CCl): ≧ 50mL/min

          -  ECOG 0 - 2

          -  Her-2 negative on endoscopic biopsy

          -  Age ≧ 20, &lt; 80

          -  Signed Informed consent form

        Exclusion Criteria:

          -  Patients with other major medical disease or malignant tumors other than gastric
             cancer

          -  Contraindication to 5-FU, Oxaliplatin, Leukovorin or Paclitaxel

          -  Pregnant, breast-feeding women or with birth plan

          -  Patients refusing treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung-Ho Kim, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sa-Hong Min, M.D.</last_name>
    <phone>82-31-787-6450</phone>
    <email>shmin823@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sa-Hong Min, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hyung-Ho Kim, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Do Joong Park, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang-Hoon Ahn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Suk Park, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yo Seok Cho, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyung-Ho Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Peritoneal carcinomatosis</keyword>
  <keyword>Intraperitoneal chemotherapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>FOLFOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

